logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12448388 B1

PDFFull Text
Date of Patent:
Oct. 21, 2025

Filed:

May. 14, 2024

Prmt5 inhibitors and uses thereof

Applicant:

Gilead Sciences, Inc., Foster City, CA (US);

Inventors:

Megan K. Armstrong, San Francisco, CA (US);

Elbert Chin, San Mateo, CA (US);

Chienhung Chou, Dublin, CA (US);

Laurent P. Debien, San Francisco, CA (US);

Yifan Deng, Milpitas, CA (US);

Joshua D. Farr, Mountain View, CA (US);

Pancham Lal Gupta, Foster City, CA (US);

Chao-I Hung, San Mateo, CA (US);

Benjamin J. June, San Francisco, CA (US);

Prasenjit K. Mukherjee, South San Francisco, CA (US);

Shaina V. Nguyen, Yorba Linda, CA (US);

Gregory T. Notte, Redwood City, CA (US);

Daniel Roa, Foster City, CA (US);

Adam J. Schrier, Redwood City, CA (US);

Katie A. Spence, San Francisco, CA (US);

Zheng-Yu Yang, Palo Alto, CA (US);

Assignee:

Gilead Sciences, Inc., Foster City, CA (US);

Attorney:
Primary Examiner:

Clinton A Brooks

Assistant Examiner:

Jerica Katlynn Wilson

Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/5383 (2006.01); A61K 31/5386 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 487/14 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/538 (2013.01); A61K 31/5383 (2013.01); A61K 31/5386 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 487/14 (2013.01); C07D 519/00 (2013.01);
Abstract

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

Find Patent Forward Citations

Loading…